Free Trial

CalciMedica Q2 2024 Earnings Report

CalciMedica logo
$1.99 -0.08 (-3.86%)
As of 03/28/2025 04:00 PM Eastern

CalciMedica EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

CalciMedica Earnings Headlines

CalciMedica Inc. Common Stock
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
CalciMedica (CALC) Projected to Post Earnings on Thursday
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

View CalciMedica Profile

More Earnings Resources from MarketBeat